Wang Yijue, Liu Yan, Gu Wenling, Cai Boyu, Lei Min, Luo Yingyu, Zhang Nannan
National Center for Birth Defect Monitoring, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China.
West China School of Stomatology, Sichuan University, Chengdu, Sichuan, China.
Front Endocrinol (Lausanne). 2025 Aug 18;16:1532682. doi: 10.3389/fendo.2025.1532682. eCollection 2025.
INTRODUCTION: The significance of immune-inflammation indexes in diabetic nephropathy (DN) was assessed in this meta-analysis to offer guidance for clinical diagnosis and treatment for DN. METHODS: We performed a meta-analysis on the association between immune-inflammation indexes and the incidence and prognosis of DN, specifically focusing on the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), systemic immune-inflammation index (SII), and systemic inflammation response index (SIRI). We thoroughly searched PubMed, Web of Science, Embase, and Cochrane from inception to September 2024. The statistical analysis was performed using R 4.2.3 software. RESULTS: 56 studies were ultimately included, comprising 50 that examined the association between DN incidence and immune-inflammation indexes and 8 that examined the association between DN prognosis and immune-inflammation indexes. The levels of NLR, MLR, PLR, and SII were significantly higher in DN patients than in non-DN ones. Besides, high NLR, MLR, SII, and SIRI were associated with elevated incidence of DN. Moreover, the high NLR group was more prone to a poor prognosis than the low NLR group (OR: 1.372, 95% CI: 1.160-1.624). CONCLUSIONS: Immune-inflammation indexes can, to a certain extent, serve as a biomarker to predict the occurrence of DN. In addition, high NLR has a potential association with the occurrence of poor prognosis in DN.
Front Endocrinol (Lausanne). 2025-8-18
J Diabetes Metab Disord. 2024-5-31
Diabetes Obes Metab. 2025-1
BMC Endocr Disord. 2024-8-20